{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T22:53:43Z","timestamp":1785020023166,"version":"3.55.0"},"reference-count":19,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Background and Clinical Significance: Zolbetuximab, a claudin 18.2-targeted monoclonal antibody, has demonstrated efficacy in advanced gastric cancer. Hypoalbuminemia has emerged as a notable adverse effect, but its underlying mechanism remains unclear. Case Presentation: A 53-year-old male with unresectable advanced gastric cancer received zolbetuximab-based combination therapy, achieving tumor regression enabling conversion surgery. During six cycles of treatment, serum albumin levels decreased from 4.3 g\/dL to 3.5-3.6 g\/dL (grade 1 hypoalbuminemia). A histopathological examination of the surgical specimen revealed hypertrophic gastritis characterized by marked foveolar hyperplasia, increased mucus secretion, and pyloric gland metaplasia on the lesser curvature. These findings suggest that zolbetuximab-induced mucosal alterations may contribute to hypoalbuminemia through enhanced protein loss. Conclusions: This is the first pathological documentation of hypertrophic gastritis associated with zolbetuximab therapy. Clinicians should monitor albumin levels during treatment and consider nutritional support when indicated. These findings provide important insights for optimizing patient management and ensuring safe conversion surgery planning.<\/jats:p>","DOI":"10.3390\/reports8040235","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T09:59:09Z","timestamp":1763027949000},"page":"235","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Mucosal Change like Hypertrophic Gastritis Following Zolbetuximab-Based Therapy in a Conversion Surgery Case of Advanced Gastric Cancer"],"prefix":"10.3390","volume":"8","author":[{"given":"Soshi","family":"Oyama","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Yamagata Prefectural Shinjo Hospital, Shinjo 996-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1975-0146","authenticated-orcid":false,"given":"Shuhei","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yamagata Prefectural Shinjo Hospital, Shinjo 996-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7349-3748","authenticated-orcid":false,"given":"Takanobu","family":"Kabasawa","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yamagata University School of Medicine, Yamagata 990-9585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kanauchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yamagata Prefectural Shinjo Hospital, Shinjo 996-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Akiba","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yamagata Prefectural Shinjo Hospital, Shinjo 996-8585, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"ref_1","unstructured":"Japanese Gastric Cancer Association (2025). Gastric Cancer Treatment Guidelines, Japanese Gastric Cancer Association. [7th ed.]."},{"key":"ref_2","unstructured":"(2025, March 20). National Cancer Center Japan, Cancer Registry and Statistics, Cancer Information Services. Hospital-Based Cancer Registry of Designated Cancer Care Hospitals, 2014\u20132015 5-Year Survival Rate Report. Available online: https:\/\/ganjoho.jp\/public\/qa_links\/report\/hosp_c\/hosp_c_reg_surv\/index.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): A multicentre, randomised, double-blind, phase 3 trial","volume":"24","author":"Rha","year":"2023","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Pellino, A., Brignola, S., Riello, E., Niero, M., Murgioni, S., Guido, M., Nappo, F., Businello, G., Sbaraglia, M., and Bergamo, F. (2021). Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. J. Pers. Med., 11.","DOI":"10.3390\/jpm11111095"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"Claudin-18, a Novel Downstream Target Gene for the T\/EBP\/NKX2.1 Homeodomain Transcription Factor, Encodes Lung- and Stomach-Specific Isoforms through Alternative Splicing","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","article-title":"Comprehensive Clinical and Molecular Characterization of Claudin 18.2 Expression in Advanced Gastric or Gastroesophageal Junction Cancer","volume":"8","author":"Kubota","year":"2023","journal-title":"ESMO Open"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 Isoform 2-Specific CAR T-Cell Therapy (SATRI-CEL) versus Treatment of Physician\u2019s Choice for Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer (CT041-ST-01): A Randomised","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global Prevalence of Claudin 18 Isoform 2 in Tumors of Patients with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in Patients with CLDN18.2-Positive, HER2-Negative, Untreated, Locally Advanced Unresectable or Metastatic Gastric or Gastro-oesophageal Junction Adenocarcinoma (SPOTLIGHT): A Multicentre, Randomised, Double-Blind, Phase 3 Trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma: The Randomized, Phase 3 GLOW Trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Kwak, Y., Kim, T.Y., Nam, S.K., Hwang, H.J., Han, D., Oh, H.J., Kong, S.H., Park, D.J., Oh, D.Y., and Lee, H.J. (2025). Clinicopathologic and Molecular Characterization of Stages II\u2013IV Gastric Cancer with Claudin 18.2 Expression. Oncologist, 30.","DOI":"10.1093\/oncolo\/oyae238"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.21873\/invivo.13900","article-title":"Safety and Feasibility of Outpatient Zolbetuximab Administration in Community Cancer Care: A Mixed-Methods Analysis","volume":"39","author":"Yakuwa","year":"2025","journal-title":"In Vivo"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/jjco\/hyaf055","article-title":"Two Cases of Protein-Losing Enteropathy Induced by Zolbetuximab in Patients with Unresectable Advanced Gastric Cancer","volume":"55","author":"Yanagimoto","year":"2025","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1056\/NEJMc2409512","article-title":"Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma","volume":"391","author":"Shitara","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_18","first-page":"424","article-title":"Primary gastric plasmacytoma: A rare cause of hypertrophic gastritis in an adolescent","volume":"29","author":"Goyal","year":"1999","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"961","DOI":"10.5009\/gnl230307","article-title":"Differential Diagnosis of Thickened Gastric Wall between Hypertrophic Gastritis and Borrmann Type 4 Advanced Gastric Cancer","volume":"18","author":"Seo","year":"2024","journal-title":"Gut Liver"}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/4\/235\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:36:54Z","timestamp":1763030214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/4\/235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["reports8040235"],"URL":"https:\/\/doi.org\/10.3390\/reports8040235","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]}}}